aminocaproic acid(redirected from Carboxylic acid derivative)
Pharmacologic class: Carboxylic acid derivative
Therapeutic class: Antihemorrhagic, antifibrinolytic
Pregnancy risk category C
Interferes with plasminogen activator substances and blocks action of fibrinolysin (plasmin)
Injection: 250 mg/ml
Syrup: 250 mg/ml
Tablets: 500 mg, 1,000 mg
⊘Indications and dosages
➣ Excessive bleeding caused by fibrinolysis
Adults: 5 g P.O. during first hour; then 1 to 1.25 g/hour until drug blood level of 0.13 mg/ml is reached and sustained and bleeding is controlled. Or 4 to 5 g in 250 ml of compatible diluent I.V. over 1 hour, followed by continuous infusion of 1 g/hour in 50 ml of diluent. Continue for 8 hours or until bleeding stops. Maximum daily dosage is 30 g.
• Dental extractions
• Hypersensitivity to drug
• Disseminated intravascular coagulation
• Neonates (injectable form)
Use cautiously in:
• heart, hepatic, or renal failure
• upper urinary tract bleeding.
• Dilute I.V. form in normal saline solution, dextrose 5% in water, or Ringer's solution for injection. Give at prescribed rate.
• Know that oral and I.V. doses are the
CNS: dizziness, malaise, headache, delirium, hallucinations, weakness, seizures
CV: hypotension, ischemia, thrombophlebitis, cardiomyopathy, bradycardia, arrhythmias
EENT: conjunctival suffusion, tinnitus, nasal congestion
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia
GU: intrarenal obstruction, renal failure
Hematologic: bleeding tendency, generalized thrombosis, agranulocytosis, leukopenia, thrombocytopenia
Musculoskeletal: myopathy, rhabdomyolysis
Respiratory: dyspnea, pulmonary embolism
Skin: rash, pruritus
Drug-drug.Estrogens, hormonal contraceptives: increased risk of hypercoagulation
Activated prothrombin, prothrombin complex concentrates: increased signs of active intravascular clotting
Drug-diagnostic tests.Alanine aminotransferase, aldolase, aspartate aminotransferase, blood urea nitrogen, creatinine, creatine kinase, potassium: increased levels
Drug-herbs.Alfalfa, anise, arnica, astragalus, bilberry, black currant seed oil, capsaicin, cat's claw, celery, chaparral, clove oil, dandelion, dong quai, evening primrose oil, feverfew, garlic, ginger, ginkgo, papaya extract, rhubarb, safflower oil, skullcap: increased anticoagulant effect
Coenzyme Q10, St. John's wort: reduced anticoagulant effect
• Monitor vital signs, fluid intake and output, and ECG.
☞ Assess for signs and symptoms of thrombophlebitis and pulmonary embolism.
☞ Monitor neurologic status, especially for signs of impending seizure.
• Monitor kidney and liver function test results, serum electrolyte levels, and CBC with white cell differential.
• Evaluate for blood dyscrasias, particularly bleeding tendencies.
• Tell patient that drug may significantly affect many body systems. Assure him that he'll be monitored closely.
☞ Instruct patient to immediately report signs and symptoms of thrombophlebitis, pulmonary embolism, or unusual bleeding.
• Tell patient he'll undergo frequent blood testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.
aminocaproic acidA drug that reduces the tendency for fibrin in the blood to be broken down. It thus aids in the clotting of blood in wounds.
aminocaproic acid (əmē´nōkəprō´ik),
drug class: hemostatic;
action: inhibits fibrinolysis by inhibiting plasminogen activator substances;
uses: hemorrhage from hyperfibrinolysis; adjunctive therapy in hemophilia; unapproved, hemorrhage following dental surgery in hemophilia.